# Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement

> **NCT06066840** · PHASE4 · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 45 (estimated)

## Conditions studied

- Safety and Efficacy

## Interventions

- **DRUG:** Basiliximab
- **DRUG:** Vedolizumab

## Key facts

- **NCT ID:** NCT06066840
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-01
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2023-10-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06066840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06066840, "Vedolizumab, Anti-CD25 Antibody, Rapid Reduction of Glucocorticoids for SR-aGVHD With Gastrointestinal Involvement". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06066840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*